Vor to participate in the jmp securities hematology and oncology summit

Cambridge, mass., nov. 29, 2021 (globe newswire) -- vor biopharma (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced that dr. robert ang, vor's president and chief executive officer, will be participating in a fireside chat at the jmp securities hematology and oncology summit.
VOR Ratings Summary
VOR Quant Ranking